Seer’s Proteograph Suite Drives Breakthroughs in Cardiovascular and Neurodegenerative Research at US HUPO 2026
Event summary
- Seer’s Proteograph Product Suite featured in over a dozen scientific presentations at US HUPO 2026, spanning cardiovascular disease, neurodegeneration, and aging biology.
- Harvard Medical School’s Dr. Sasha A. Singh to present on profiling plasma in atherosclerosis models using Seer’s technology, quantifying over 5,000 proteins from 75 µL samples.
- NIH’s Dr. Nathan Basisty to discuss proteomics in translational geroscience during a plenary session.
- Seer hosting a breakfast symposium on cardiovascular disease research and showcasing its technology at Booth #18.
The big picture
Seer’s participation in US HUPO 2026 underscores the increasing role of deep, scalable proteomics in translational research. The company’s Proteograph Product Suite is positioning itself as a critical tool for advancing cardiovascular and neurodegenerative research, potentially expanding its footprint in high-growth disease areas. The strategic importance of Seer’s technology lies in its ability to bridge laboratory discoveries with clinical applications, a key differentiator in the competitive proteomics market.
What we're watching
- Technology Adoption
- How the growing adoption of Seer’s Proteograph Product Suite will impact its market position in scalable proteomics.
- Research Validation
- Whether the scientific validation at US HUPO 2026 will translate into increased demand from academic and clinical researchers.
- Competitive Differentiation
- The pace at which Seer can sustain its technological edge in deep, unbiased proteomics against emerging competitors.
Related topics